Page last updated: 2024-10-31

methylphenidate and Cardiovascular Diseases

methylphenidate has been researched along with Cardiovascular Diseases in 19 studies

Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.

Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.

Research Excerpts

ExcerptRelevanceReference
" While medications for ADHD are generally well-tolerated, there are common, although less severe, as well as rare but severe adverse events AEs during treatment with ADHD drugs."2.49Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. ( Banaschewski, T; Buitelaar, J; Coghill, D; Cortese, S; Danckaerts, M; Dittmann, RW; Graham, J; Holtmann, M; Sergeant, J; Taylor, E, 2013)
" A recorded diagnosis (either a primary or secondary cause) of any of the following cardiovascular adverse events: arrhythmias (ICD-10 (international classification of diseases, 10th revision) codes I44, I45, I47, I48, I49), hypertension (codes I10-I15), myocardial infarction (code I21), ischemic stroke (code I63), or heart failure (code I50)."1.43Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. ( Park, BJ; Pratt, NL; Roughead, EE; Shin, JY, 2016)
" During the treatment period the investigators titrated the OROS-MPH dosage on the basis of symptom severity and side effects."1.38Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment. ( Bellgrove, MA; Cho, SC; Cummins, TD; Kim, BN; Kim, JW, 2012)

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19902 (10.53)18.7374
1990's0 (0.00)18.2507
2000's2 (10.53)29.6817
2010's15 (78.95)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alrwisan, AA1
Wei, YJ1
Brumback, BA1
Antonelli, PJ1
Winterstein, AG3
Aries, E1
El Louali, F1
Ovaert, C1
Antel, J1
Albayrak, Ö1
Heusch, G1
Banaschewski, T3
Hebebrand, J1
Guertin, J1
LeLorier, J1
Durand, M1
Gow, R1
Holbrook, A1
Levine, M1
Knecht, KR1
Chen, CY1
Bussing, R1
Hartzema, AG1
Shuster, JJ1
Segal, R1
Jackson, JW1
Shin, JY1
Roughead, EE1
Park, BJ1
Pratt, NL1
Hennessy, S1
Schelleman, H1
Daniel, GW1
Bilker, WB1
Kimmel, SE1
Guevara, J1
Cziraky, MJ1
Strom, BL1
Cho, SC1
Kim, BN1
Cummins, TD1
Kim, JW1
Bellgrove, MA1
Olfson, M1
Huang, C1
Gerhard, T1
Crystal, S1
Allison, PD1
Marcus, SC1
Cortese, S1
Holtmann, M1
Buitelaar, J1
Coghill, D1
Danckaerts, M1
Dittmann, RW1
Graham, J1
Taylor, E1
Sergeant, J1
Kraut, AA1
Langner, I1
Lindemann, C1
Petermann, U1
Petermann, F1
Mikolajczyk, RT1
Garbe, E1
Arcieri, R1
Germinario, EA1
Bonati, M1
Masi, G1
Zuddas, A1
Vella, S1
Chiarotti, F1
Panei, P1
Sussman, S1
Pentz, MA1
Spruijt-Metz, D1
Miller, T1
Langendijk, PN1
Wilde, AA1
Jaffe, RB1
Bennett, HD1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Therapeutic Use of Repetitive Transcranial Magnetic Stimulation (rTMS) in Pediatric Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Cohorts (ADHD): a Randomized, Sham-controlled Study.[NCT06069323]80 participants (Anticipated)Interventional2023-06-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

4 reviews available for methylphenidate and Cardiovascular Diseases

ArticleYear
Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?
    European archives of psychiatry and clinical neuroscience, 2015, Volume: 265, Issue:3

    Topics: Adolescent; Adult; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Blood Press

2015
Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents.
    Journal of child psychology and psychiatry, and allied disciplines, 2013, Volume: 54, Issue:3

    Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure

2013
Misuse of "study drugs:" prevalence, consequences, and implications for policy.
    Substance abuse treatment, prevention, and policy, 2006, Jun-09, Volume: 1

    Topics: Adolescent; Adult; Amphetamines; Cardiovascular Diseases; Central Nervous System Stimulants; Emotion

2006
Cardiac and vascular involvement in drug abuse.
    Seminars in roentgenology, 1983, Volume: 18, Issue:3

    Topics: Adult; Aneurysm, Infected; Arterial Occlusive Diseases; Arteriovenous Fistula; Cardiomyopathies; Car

1983

Other Studies

15 other studies available for methylphenidate and Cardiovascular Diseases

ArticleYear
Concomitant Use of Quinolones and Stimulants and the Risk of Adverse Cardiovascular Symptoms: A Retrospective Cohort Study.
    Pharmacotherapy, 2019, Volume: 39, Issue:12

    Topics: Adolescent; Adult; Aged; Amphetamines; Anti-Bacterial Agents; Arrhythmias, Cardiac; Cardiovascular D

2019
[ECG before administration of Ritalin
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2017, Volume: 24, Issue:7

    Topics: Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Electrocardiography; Humans;

2017
Impact of a restrictive drug access program on the risk of cardiovascular encounters in children exposed to ADHD medications.
    Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique, 2014, Volume: 21, Issue:3

    Topics: Adolescent; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity;

2014
Cardiovascular safety of stimulant medications.
    Journal of child and adolescent psychopharmacology, 2015, Volume: 25, Issue:2

    Topics: Adolescent; Cardiovascular Diseases; Central Nervous System Stimulants; Child; Humans; Methylphenida

2015
Stimulant use following the publicity of cardiovascular safety and the introduction of patient medication guides.
    Pharmacoepidemiology and drug safety, 2016, Volume: 25, Issue:6

    Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Central Nervou

2016
The cardiovascular safety of methylphenidate.
    BMJ (Clinical research ed.), 2016, May-31, Volume: 353

    Topics: Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Central Nervous System Stimu

2016
Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study.
    BMJ (Clinical research ed.), 2016, May-31, Volume: 353

    Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Case-Control Stu

2016
Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study.
    Pharmacoepidemiology and drug safety, 2010, Volume: 19, Issue:9

    Topics: Adolescent; Adrenergic Uptake Inhibitors; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit

2010
Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.
    Journal of psychopharmacology (Oxford, England), 2012, Volume: 26, Issue:3

    Topics: Attention Deficit Disorder with Hyperactivity; Blood Pressure; Cardiovascular Diseases; Child; Delay

2012
Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2012, Volume: 51, Issue:2

    Topics: Adolescent; Amphetamines; Angina Pectoris; Arrhythmias, Cardiac; Attention Deficit Disorder with Hyp

2012
Encouraging news about ADHD drugs and heart risk in adults.
    The Harvard mental health letter, 2012, Volume: 28, Issue:9

    Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Central Ne

2012
Comorbidities in ADHD children treated with methylphenidate: a database study.
    BMC psychiatry, 2013, Jan-07, Volume: 13

    Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Case-Control Stu

2013
Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine.
    Journal of child and adolescent psychopharmacology, 2012, Volume: 22, Issue:6

    Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with

2012
[Medication for ADHD and the risk of cardiovascular mortality].
    Nederlands tijdschrift voor geneeskunde, 2006, Aug-05, Volume: 150, Issue:31

    Topics: Amphetamine; Arrhythmias, Cardiac; Attention Deficit Disorder with Hyperactivity; Cardiovascular Dis

2006
The management of massive gastrointestinal bleeding in the aged patient.
    Geriatrics, 1967, Volume: 22, Issue:3

    Topics: Aged; Blood Volume Determination; Cardiovascular Diseases; Cerebrovascular Disorders; Chromium Isoto

1967